- Pending Home Sales Have Record Rise; Construction Flat
- Commercial Property Fears Are Overblown: Zell, LeFrak
- Trump: Time to Force Banks to Start Lending
- Accused Fraudster Rothstein Arrested
- More Late on Auto Loan Payments in Third Quarter
- Treasury to Sell 12.7 Million Capital One Warrants
- Contagion Fears Calmed by Dubai World Plan
- AIG Cuts Debt to Government by $25 Billion; Shares Up
- GM Sees China Sales Soar 110% in November
- Farrell: Forget About Dubai—Worry About This
- How Long Will This Health Care Firm's Rally Last?
- Dubai a 'Wake Up Call'—Expect Volatility Now: Market Pro
- Treasury Threatens Banks, Not Borrowers
- We're Approaching a Market Bubble: Portfolio Manager
- Hershey Shares: What Options Are Saying
- Nov. 30: Unusual Volume Leaders
- Why Careful Shoppers Are Great for the Box Office
- Blue Nile CEO: 'We're Having the Best Cyber Monday Ever'
MOST SHARED
- Good Sign for the Economy: 'Greed' Makes a Comeback
- Commercial Property Fears Are Overblown: Zell, LeFrak
- Dubai Stocks Could Fall a Further 30%: Charts
- Manufacturing in Focus as Bulls Call for Turn in Dollar
- Bank of Japan Offers More Liquidity at Emergency Meeting
- Dubai Markets Close Sharply Lower for Second Day
- Timeless and Time-Tested Warren Buffett Watch Predictions
- AIG Cuts Debt to Government by $25 Billion; Shares Up
- More Late on Auto Loan Payments in Third Quarter
- Bove: 26 Banks May Need To Raise More Capital
Text Size 
Giving everyone who's admitted to a hospital a quick test for the so-called "Superbug" doesn't significantly cut the number of infections and isn't cost-effective.
That's the conclusion of the biggest study yet that's just been published in the Journal of the American Medical Association. The journal also says in an editorial that hospitals can control the potentially fatal staph infections by using basic sanitary measures rather than "expensive" tests.
Researchers looked at nearly 22-thousand patients at a Swiss hospital who either got screened for the bacterial infection commonly known as MRSA or who used standard infection controls like hand gel. And they report that the universal testing did not reduce the incidence of MRSA infections.
Cepheid [CPHD
Loading...
()
] and Becton Dickinson [BDX
Loading...
()
] make MRSA tests which can give results much faster than the one used in the study and a few other companies are working on next-generation screening systems.
Cepheid CEO John Bishop told CNBC, "To say that it's (the MRSA test) not effective is an overstatement." Mr. Bishop said that MRSA is much less prevalent in Switzerland than in the U.S., so he argues it is much more difficult to show a reduction in infection rates in Switzerland than it is here.
In an email, Becton says this is just one "data point" and that many other studies have shown that testing for MRSA saves lives and money.
Print
Email
- Goldman Sachs has forbidden employees from gathering in private holiday parties of 12 or more.
- Since its launch in 1998, Google has become a primary force on the Internet. How much do you know about the company?
- What do the gifts from the 12 Days of Christmas cost this year, and how do they compare to 2008?
- Raising alligators is hard work, and the fickle taste of rich consumers has just made it much harder, says the NY Times.
- A recent issue of ESPN Magazine was one of its top sellers ever, and it only took scantily clad athletes to make it happen.
- The continued real estate boom in China is partially fueled by a generational flood of newlyweds.
Data is a real-time snapshot *Data is delayed at least 15 minutes